Can a New CEO Turn Around Teva?
Often companies that lose their way or face adversity may need a change at the top. Teva Pharmaceutical seems to be the perfect example, and with its change investors are sending the shares much…
All Work
Chris Lange
Marinus Pharma Wins Big With Mid-Stage Epilepsy Study
Marinus Pharmaceuticals saw its shares make a huge gain to kick off the week after the firm announced top-line results from its mid-stage study in patients with CDKL5 disorder.
Despegar Finally Prices IPO
Despegar.com intends to price more than 12 million shares in a range that results in an initial public offering valued up to almost $382 million.
Achillion Pharma Slides After Hep C Deal Is Terminated
Achillion Pharmaceuticals saw its shares slump early on Monday after the firm announced that its hepatitis C license and collaboration agreement with Janssen had been terminated.
5 Stocks That Tanked the Dow Last Week
The Dow Jones Industrial Average just had its worst weekly drop since March. Here’s a look at the stock brought the index down over this past week.
Tech Analyst Calls That Absolutely Cannot Be Ignored
24/7 Wall St. has put together a look at a few widely influential analyst calls over this past week on some of the biggest names in the tech sector.
Why Zumiez Earnings Are So Great
Zumiez shares were up sharply since it reported its fiscal second-quarter financial results after the markets closed Thursday.
Kura Oncology Doubles on Mid-Stage Trial Results
Kura Oncology saw its shares double early Friday after the firm announced results from its mid-stage trial in patients with squamous cell carcinomas.
MPM Files for IPO
Global chemicals manufacturer MPM has filed with the SEC regarding an initial public offering.
Kroger Q2 Earnings Not Enough to Impress Investors
Kroger released quarterly results that were essentially in line with expectations and offered guidance early Friday.
Thursday’s Biggest Winners and Losers in the S&P 500
Thursday was a mixed day for the U.S. broad markets with all major indices starting off positive, but quickly souring with the exception of the Nasdaq. Crude oil backed off after posting a few…
Why Kroger Earnings Can Stand Up to Amazon’s Onslaught
Grocery stores, among other industries, have been under attack by the unending onslaught of Amazon, especially after the Whole Foods acquisition.
How Bristol-Myers Actually Won by Stopping a Clinical Study
Usually when a clinical study is stopped it spells disaster for the company performing the study, but in this case Bristol-Myers Squibb is bucking that trend and investors are thrilled.
Celgene Faces Multiple Clinical Holds From FDA
Celgene received an update from the FDA early on Thursday. Although shares did not dip initially, this action could prove to be problematic for the biotech giant going forward.
Best Prices IPO Over $1 Billion
Best intends to price more than 62 million American depositary shares in the range of $13 to $15 apiece for an initial public offering valued up to about $1 billion.
Can GoPro Maintain a Profitable Turnaround?
GoPro saw its shares make a handy gain early on Thursday after the firm commented on its guidance for the third quarter.
How Apple Plans to Return $300 Billion to Shareholders
In an effort to further fund its capital return program, among other things, Apple has announced that it is issuing a debt offering.
Wednesday’s Biggest Winners and Losers in the S&P 500
Wednesday was a very positive day for the U.S. broad markets almost making up for the incredible loss that we saw on Tuesday. Crude oil continued its run to the $50 price level, and…
Why Verastem Is Knocking It Out of the Park
Verastem saw perhaps the biggest gain in the market Wednesday after the company announced positive late-stage results.
Can Gap’s New Long-Term Strategy Pay Off?
What’s pushing Gap stock higher is a new long-term plan that the executive management team has put together. Investors seem pretty thrilled about this plan, but will it succeed?